Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?
Authors
Keywords
Toxicity, Drug metabolism, Genetic polymorphism, Chemotherapy, Colorectal cancer, Cancer chemotherapy, Predictive toxicology, Cancer treatment
Journal
PLoS One
Volume 11, Issue 9, Pages e0163105
Publisher
Public Library of Science (PLoS)
Online
2016-09-23
DOI
10.1371/journal.pone.0163105
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Upfront Genotyping ofDPYD*2Ato Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
- (2016) Maarten J. Deenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer
- (2015) Nai-Chun Wu et al. ANTI-CANCER DRUGS
- Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
- (2015) M. Joerger et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
- (2015) Giuseppe Toffoli et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
- (2015) Didier Meulendijks et al. LANCET ONCOLOGY
- A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS
- (2014) Dan Rosmarin et al. GUT
- Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
- (2014) Dan Rosmarin et al. JOURNAL OF CLINICAL ONCOLOGY
- MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland
- (2014) Amit A. Negandhi et al. PLoS One
- Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
- (2013) A Loganayagam et al. BRITISH JOURNAL OF CANCER
- Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population
- (2013) Moon Ju Jang et al. GENE
- Thymidylate Synthase Gene Polymorphism and Survival of Colorectal Cancer Patients Receiving Adjuvant 5-Fluorouracil
- (2013) Violetta Sulzyc-Bielicka et al. Genetic Testing and Molecular Biomarkers
- Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China
- (2013) Lin Zhu et al. MEDICAL ONCOLOGY
- Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer
- (2013) Jing Zhao et al. MEDICAL ONCOLOGY
- An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens
- (2013) Ying-Chao Wang et al. MOLECULAR BIOLOGY REPORTS
- Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry
- (2012) Maarten J. Deenen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer
- (2011) F Thomas et al. BRITISH JOURNAL OF CANCER
- Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan
- (2011) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Combinations of Polymorphisms in Genes Involved in the 5-Fluorouracil Metabolism Pathway Are Associated with Gastrointestinal Toxicity in Chemotherapy-Treated Colorectal Cancer Patients
- (2011) S. Afzal et al. CLINICAL CANCER RESEARCH
- Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
- (2011) M. J. Deenen et al. CLINICAL CANCER RESEARCH
- Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study
- (2010) A. Tsunoda et al. ANNALS OF ONCOLOGY
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
- (2009) W Chua et al. BRITISH JOURNAL OF CANCER
- Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy
- (2009) Antonia M. Fernández-Peralta et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells
- (2009) Alfonso M Lostia et al. THERAPEUTIC DRUG MONITORING
- Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients
- (2008) R. Sharma et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started